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Abstract
Background: Trachoma, the worldwide leading infectious cause of blindness, is due to repeated conjunctival infection with
Chlamydia trachomatis. The effects of control interventions on population levels of infection and active disease can be
promptly measured, but the effects on severe ocular sequelae require long-term monitoring. We present an age-structured
mathematical model of trachoma transmission and disease to predict the impact of interventions on the prevalence of
blinding trachoma.
Methodology/Principal Findings: The model is based on the concept of multiple reinfections leading to progressive
conjunctival scarring, trichiasis, corneal opacity and blindness. It also includes aspects of trachoma natural history, such as an
increasing rate of recovery from infection and a decreasing chlamydial load with subsequent infections that depend upon a
(presumed) acquired immunity that clears infection with age more rapidly. Parameters were estimated using maximum
likelihood by fitting the model to pre-control infection prevalence data from hypo-, meso- and hyperendemic communities
from The Gambia and Tanzania. The model reproduces key features of trachoma epidemiology: 1) the age-profile of infection
prevalence, which increases to a peak at very young ages and declines at older ages; 2) a shift in this prevalence peak, toward
younger ages in higher force of infection environments; 3) a raised overall profile of infection prevalence with higher force of
infection;and 4)a risingprofile, withage, of the prevalence ofthe ensuingsevere sequelae (trachomatousscarring, trichiasis),as
well as estimates of the number of infections that need to occur before these sequelae appear.
Conclusions/Significance: We present a framework that is sufficiently comprehensive to examine the outcomes of the A
(antibiotic) component of the SAFE strategy on disease. The suitability of the model for representing population-level
patterns of infection and disease sequelae is discussed in view of the individual processes leading to these patterns.
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Introduction
Trachoma is the leading infectious cause of blindness in the
world; 8 million people are blind or severely visually impaired due
to trachoma and 63 million have active disease [1]. It is due to
repeated conjunctival infection with the bacterium Chlamydia
trachomatis, and the ‘‘SAFE’’ control strategy (surgery, antibiotics,
facial cleanliness and environmental improvement) is recommend-
ed by the World Health Organization (WHO) [2]. The effects of
control programs on community infection and active disease can
be rapidly measured, but their effects on the severe sequelae
(trichiasis, corneal opacity and blindness) will not be properly
ascertained until decades after their implementation, so mathe-
matical modeling provides an invaluable method for the prediction
of program performance.
Previous mathematical models of trachoma infection at the
population level have primarily looked at the effects of treatment
with antibiotics, and the rebound in the prevalence of active
disease that follows treatment cessation [3–6]. However, no model
has taken into account the important effects upon infection and
disease of the apparent increase in the rate of bacterial clearance
that is observed with age. On the one hand, this shortening of
www.plosntds.org 1 June 2009 | Volume 3 | Issue 6 | e462clearance time is thought to be attributable to an acquired, yet not
protective, immune response that is enhanced with repeated
exposure to C. trachomatis [3,7]. On the other hand, the
mechanisms responsible for bacterial clearance may also be
immunopathological, and they may lead to scarring and
subsequent disease sequelae that are associated with trachoma
[8]. Therefore, episodes of repeated infection and clearance of C.
trachomatis may lead to the more severe complications of the
disease: trachomatous scarring (TS), trachomatous trichiasis (TT),
corneal opacity (CO) and, eventually, blindness. In order to
predict the impact of treatment on scarring sequelae, which are
the focus of the Alliance for the Global Elimination of blinding
Trachoma by 2020 (GET 2020) [9], models need to incorporate
contemporary understanding of the relationship between infection,
disease, and disease progression.
A mathematical model of ocular infection with C. trachomatis was
developed, and its parameters were estimated through fitting the
model to pre-intervention ocular chlamydial infection prevalence,
rate of recovery from infection, and infection load data from three
geographically-separate study sites in The Gambia and Tanzania,
representing areas of low, moderate and high endemicity. Insights
from the model help explain observed age-profile patterns of
infection prevalence in these settings. Progression of individuals to
greater numbers of infections, through repeated infection, is
interpreted as leading to worsening scarring. Therefore, the model
population that has progressed to various numbers of repeat
infection represents the population suffering from each of the
severe disease sequelae; the corresponding age-profiles of disease
prevalence are then compared with clinico-epidemiological data.
Finally, the degree to which the model captures the epidemiolog-
ical patterns of infection and disease observed, and the possible
causes for discrepancy are discussed.
Methods
Model Development
The model developed here represents ocular infection with C.
trachomatis in a community setting and is based upon a framework
commonly used in the modeling of microparasitic infections [10].
In the model, susceptible (S) individuals become infected through
contact with infected (I) individuals before recovering again to a
susceptible state. Initial infection and reinfection occur through
direct contact with other infected members of the community
whereas indirect contact can occur through inanimate objects
capable of carrying infection from an infected person to another
person or through facial contact with flies carrying the bacteria
[11,12]. In endemic settings, disease progression appears to occur
through multiple reinfection [13,14]. Therefore, the model takes
account of the importance of multiple reinfections on disease
progression by keeping track of the number of infections an
individual has experienced. Superinfection of an already-infected
individual with a different strain of C. trachomatis, which does occur
in endemic villages [15], is ignored at this stage. Conceptually, the
model represents a ‘ladder’ of infection, with each ‘rung’ of the
infection ladder corresponding to an additional cumulative
infection with C. trachomatis (Figure 1). Susceptible states are
denoted by Si and infected states by Ii, with subscript i denoting
the number of previous infections experienced (full details of the
model are given in Text S1). As individuals progress to the next
state up the ladder of infection, a memory of the number of
infections experienced is retained.
Since birth and death rates are important when determining
prevalence levels of the more severe disease sequelae, the
demography of the population is included in the model. The
disease sequelae are more prevalent at older ages and, once the
population has had the antibiotic component of the SAFE strategy
successfully implemented, we assume that the rate at which disease
prevalence levels decline depends upon mortality among older
individuals. Age-specific death rates and the crude birth rate for
The Gambia and Tanzania were based on WHO life table
estimates for the year 2001 [16].
It is the explicit inclusion of disease sequelae, age structure,
differential infectivity and immunity considerations that distin-
guish this model from those that have been previously reported
[5,6]. The equilibria of the model will provide a representation of
the way in which each of these forces are balanced in the endemic
state.
Rate of Recovery and Infection Load
Several studies have postulated that the sequelae of trachoma
are caused by immunopathological processes that increase in
severity with increasing age [17–19]. This idea is supported by
work which shows that the duration of episodes of infection and
active disease (the latter encompassing trachomatous follicular and
severe papillary conjunctivitis) becomes markedly shorter with
increasing age [3,7]. In this paper, it is assumed that adaptive
immunity does not protect from acquiring infection but results in
an increasing rate of recovery from infection as the number of
previous infections increases; such a framework was chosen here
due to the limited evidence for protective immunity against
infection [20] and the preference for a parsimonious model. In
Figure 1 the recovery rate from infection Ii is denoted by ui. This
recovery rate approaches a limit at high numbers of infections.
The parameter values determining: 1) the rate at which the curve
rises with infection number; 2) the initial recovery rate; and 3) the
recovery rate following a large number of infections, were
estimated using maximum likelihood by fitting the model to data
on the prevalence of infection as detailed in the Text S1.
In trachoma-endemic communities, bacterial infection load
among individuals at young ages is higher than that at older ages
[21–23]. In the model presented here, this decrease in infection
load with age is ascribed to the acquired immune response to
chlamydial infection that is developed through bacterial reinfec-
Author Summary
Trachoma is the worldwide leading infectious cause of
blindness and is due to repeated conjunctival infection with
Chlamydia trachomatis bacteria. The effects of control
interventions on population levels of infection and active
disease can bepromptlymeasured,butthe effectsonsevere
ocular disease outcomes require long-term monitoring. We
present a mathematical model of trachoma transmission
and disease to predict the impact of interventions on
blinding trachoma. The model is based on the concept of
multiple re-infections leading to progressive scarring of the
eye and the potentially blinding disease sequelae. Itincludes
aspects of trachoma natural history such as an increasing
rate of recovery from infection, and a decreasing chlamydial
load with subsequent infections. The model reproduces key
features of trachoma epidemiology such as the age-profile
ofinfectionprevalence;ashiftintheprevalencepeaktoward
younger ages in higher-transmission environments; and a
rising profile of the prevalence of the severe sequelae
(scarring, trichiasis), as well as estimates of the number of
infections experienced before these sequelae appear. The
model can be used to examine the outcomes of various
control strategies on infection and disease and can help to
plan treatment interventions for different endemic settings.
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represent the average infection load for an individual who has
experienced a given number of infections. The chlamydial load
enters the model as a proxy for the infectivity of individuals; those
who have experienced fewer infections have a higher infection
load than those who have experienced many and are therefore
more infectious.
Prevalence of Disease Sequelae
The model assumes that scarring worsens through repeat
infection with C. trachomatis and that, as scarring (TS) becomes
worse, the more severe disease sequelae (TT and CO) occur.
However, due to the complex etiology of CO—reinfection is
almost certainly not the only causal factor—only TS and TT are
considered in the model, which is entirely based on the reinfection
route. It is assumed that these conditions co-occur, so that an
individual may have scarring, or scarring and trichiasis. In each
case, it is assumed that where TT is present, TS will also be
present (Figure 2).
Infection and Disease Prevalence
The model was fitted using maximum likelihood to pre-
intervention prevalence and chlamydial load data collected in
studies carried out in The Gambia and Tanzania, the details of
which have been described by Burton et al. [22], Solomon et al.
[21,24], and West et al. [25] (Table 1). In these studies community
infection prevalence was determined by qualitative PCR and the
individual infection load by quantitative PCR (in the case of the
hyperendemic Tanzanian community, a model fit was also
obtained for which quantitative PCR was used to measure both
prevalence and load; further details of these are available in Text
S1). These community data-sets illustrate the general differences
between three distinct endemic levels while not necessarily being
representative of all hyper-, meso- and hypoendemic communities.
The model was first fitted using maximum likelihood to the
hyperendemic data set for which three distinct data types were
available: age-profiles of the prevalence of infection and the
infection load from a community in Tanzania [25], and the rate of
recovery from infection based on a cohort study with frequent
follow up in The Gambia [3]. A likelihood expression was
formulated that combined all three data types and the prevalence,
infection load, and duration of infection data were assumed to
arise from binomial, Poisson and exponential distributions
respectively. The Poisson distribution was selected in the absence
of information regarding the distribution of the infection load for
each infection category i; and an exponential distribution was used
for the duration of infection data consistent with the model
structure. The likelihood framework is outlined in Text S1.
Likelihood expressions were formulated for each of the data sets
and the overall log-likelihood (LL) formed by summing the
individual LLs—and assuming that measurements of prevalence
and load were independent of one another (Text S1)—so that:
LLtotal~LLprevalencezLLloadzLLrecovery ð1Þ
Figure 2. Incorporating disease sequelae into the model. A
schematic representation of the way in which the model determines
the presence of disease sequelae: trachomatous scarring (TS) and
trachomatous trichiasis (TT) (TS and TT—but not corneal opacity, CO—
are considered to be caused exclusively by reinfection with C.
trachomatis). The simplest scheme is used: thresholds exist, along the
ladder of infection, beyond which each of the sequelae are assumed to
be present. Beyond the threshold corresponding to a specific sequela,
that sequela is assumed to be observed, e.g. when the threshold for TT
has been reached, both TT and TS are observed.
doi:10.1371/journal.pntd.0000462.g002
Figure 1. Compartmental diagram of the model. A compartmental diagram illustrating the model described in the text. Each susceptible and
infected compartment is connected to the compartment above so that the population passes up a ‘ladder’ of infection. The subscript i corresponds
to the number of prior infections experienced.
doi:10.1371/journal.pntd.0000462.g001
Model of Trachoma Transmission Dynamics
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parameters (listed in Table 2) pertaining to the three data types.
Parameter values and their 95% confidence intervals (found using
the profile-likelihood around the maximum LL value) are provided
in Table 2. For each parameter, the profile likelihood was
calculated by fixing the parameter and maximizing the LL with
respect to all of the other parameters. Aside from the transmission
parameter (b), the parameter estimates thus obtained were then
used in modeling the meso- and hypoendemic settings (defined as
those exhibiting an active disease prevalence lower than 10% and
between 10 and 20% respectively (Table 1)) since they pertain to
the biology and not to the transmission environment of the
infection. Transmission parameters were then obtained separately
for the hypo- and mesoendemic datasets based on maximum
likelihood fitting to the prevalence data alone from each area. The
pattern of population mixing among ages was assumed to lie
between the extremes of entirely random and fully assortative [26].
The model was implemented in Matlab using the Euler integration
method; the LL maximization was also performed using the
Matlab package.
Results
Model Fit to Age-Profiles of Prevalence of C. trachomatis
Infection by Endemicity Level
The curves shown in Figure 3A and 3B represent the model-
generated age-profiles of the infection load and the rate of
recovery from infection based on the maximum likelihood
parameters obtained from the analysis of data from the
hyperendemic setting (i.e. as in Table 2). These curves show the
previously described reduction in infection duration and intensity
with age and the parameters thus obtained were used for all
subsequent modeling. Model fits to the data by endemicity level
are shown in Figure 4. The solid line in Figure 4A illustrates the
model-generated infection prevalence curve corresponding to the
fit to the hyperendemic data set published by West et al. [25]. The
dotted line in Figure 4A is an illustrative fit obtained assuming a
lower number of individuals in each age-group classified as
positive for infection (see Text S1 for details). The transmission
parameter b estimated for this adjusted dataset is approximately
two thirds the size of the value shown in Table 2. Figure 4B and
4C illustrate the model-generated infection prevalence curves for
the model fitted to the hypo- and mesoendemic datasets (i.e. using
the endemic-specific transmission parameter estimate but the
infectivity and rate of recovery parameter estimates obtained from
the analysis of the data from the hyperendemic setting). Figure 3B
shows that the duration of chlamydial infection declines from its
initial maximum value to its plateau very rapidly with age, and this
is due to the rapid decrease in this value with infection number.
The infection prevalence data come to a peak at young ages
(roughly 5 years) in the hypo- and mesoendemic areas examined
here, with model fits mirroring such peaks. Furthermore, the data
also show some evidence for a peak shift [27], characterized by the
peak of infection being shifted towards younger ages as
transmission levels increase (Figure 4).
Threshold Number of Infections for the Manifestation of
Disease Sequelae
The threshold numbers of infections necessary for individuals to
show signs of each of the sequelae were calculated for the
hyperendemic setting. These thresholds were estimated by
maximum likelihood using the published data of Munoz et al.
Table 1. Summary of the infection and disease levels for the data-sets used in this study.
Location and country Infection prevalence Active disease prevalence Source Endemicity level
Upper Saloum district, The Gambia 7% 8% [22] Hypoendemic (,10% active disease)
Rombo district, Tanzania 10% 18% [24] Mesoendemic (10–20% active disease)
Kongwa district, Tanzania 52% 36% [25] Hyperendemic (.20% active disease)
Provenance of the data from three trachoma-endemic regions that are used in this paper for model fitting. Active disease is measured as trachoma follicular (TF) and/or
trachoma inflammation (TI) on the World Health Organization simplified grading scheme [43].
doi:10.1371/journal.pntd.0000462.t001
Table 2. Model parameter definitions and estimates.
Parameter Parameter definition Maximum likelihood estimate [95%CI] and units
1=u1 Mean duration of first infection 15.1 [6.5,23.3] months
1=u? Mean duration of infection after multiple prior infections 2.8 [2.4, 3.2] months
c Rate of drop of duration of infection per prior infection 0.7 [0.1,‘] infection
21
l1 Infection load per person at first infection 1.0610
5[0.9, 1.3610
5] copies C.trachomatis omp1 gene per ocular swab
w Rate of drop of infection load per prior infection 0.05 [0.03, 0.07] infection
21
b Transmission coefficient: the rate of transmission (per year) of infection
between individuals
Hyperendemic: 27.7 [21.8, 35.1] year
21
Mesoendemic: 2.4 [2.0, 2.9] year
21
Hypoendemic: 1.8 [1.6, 2.1] year
21
Parameter definitions and estimates, with 95% confidence intervals, for the model obtained through maximum likelihood fitting using a function combining infection
prevalence, bacterial load, and recovery rate data from a hyperendemic setting in Tanzania. The transmission parameters for the meso- and hypoendemic settings were
estimated by maximum likelihood by fitting to prevalence data only. The parameter symbols refer to the model definition detailed in Text S1.
doi:10.1371/journal.pntd.0000462.t002
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sequelae. The maximum likelihood estimate for the threshold
number of infections required for TS was 102 and for TT it was
151. In terms of the natural history of trachoma infection,
disease, and disease sequelae, it is assumed here that these
threshold values do not vary over the different endemicity levels
but should be reached at different ages according to the intensity
of transmission—individuals living in areas of different ende-
micity are assumed to show signs of each of the disease sequelae
after having experienced the same number of infections, but they
experience the sequelae earlier in their lives in those environments
in which they are infected more frequently. The threshold
infection numbers estimated here were used to generate the
curves shown in Figure 5.
Discussion
The model presented in this paper reproduces many important
aspects of trachoma epidemiology, namely: 1) the pattern of the
prevalence of infection with age, which peaks at very young ages
and then declines; 2) a peak shift towards younger ages in this
prevalence in higher transmission settings; 3) a rise of the
prevalence level with higher transmission; and 4) a rise with age
of the prevalence of the severe disease sequelae. The model also
allows estimates to be made of the threshold number of infections
necessary for the appearance of the severe disease sequelae.
Infection and disease profiles were obtained assuming long-term
stability of prevalence levels in the model, and therefore represent
the equilibrium, pre-intervention state in each of the endemicity
Figure 3. Model fits to hyperendemic data. Age-profiles generated by the maximum likelihood parameter estimates to the hyperendemic data
set of West et al. [25] and—for the recovery rate—Bailey et al. [7], re-analyzed by Grassly et al. [3] (data displayed as square data points with 95%
confidence intervals, and model fits shown as solid lines): A) the infectivity, which is proportional to the bacterial load, measured by quantitative PCR;
B) duration of infection.
doi:10.1371/journal.pntd.0000462.g003
Figure 4. Model fits to data from three endemic settings. Age-profiles of the prevalence of infection generated by fitting the model (solid
lines) to the data (squares and 95% confidence interval error bars) from (A) Kongwa, Tanzania [25] (B) Rombo, Tanzania [24] and (C) Upper Saloum,
The Gambia [22]. The dotted line in (A) corresponds to a model-fit to the data from Kongwa, Tanzania assuming a lower number of true infection
positives, namely those that were determined to harbour chlamydial loads as measured by quantitative PCR (see main text and Text S1). Note the
different scale on the y-axis of (A) in comparison to (B) and (C).
doi:10.1371/journal.pntd.0000462.g004
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parameters is that in some areas (e.g., The Gambia), there have
been secular trends towards a decrease of trachoma incidence in
the absence of control interventions. These trends are deemed
much less significant in the hyperendemic setting.
Following the fitting of the model to the data-sets from the three
endemic settings, the prevalence curves generated show a close
correspondence with the trend in the observed profiles of infection
prevalence with age. While good visual fits to the data are
encouraging, a full analysis of the uncertainty in the parameter
estimates is essential to judge how well-determined the model fits
are. In the younger ages, the prevalence peak is caused by the long
duration of infection, high chlamydial loads and intense
transmission that result from patterns of assortative mixing by
age. Subsequently, the prevalence of infection drops at older ages,
as a consequence of the age-associated increase in the recovery
rate from infection and the drop in infectivity with age: an
individual who experiences an increasing number of infections
recovers faster from each infection, with accompanying reductions
in chlamydial load and infectivity. (In the model, the number of
infections previously experienced tracks closely the age of an
individual.) There is also a peak shift of the maximum infection
prevalence towards younger ages (slightly greater than 5 years of
age in the hypoendemic; slightly under 5 years in the mesoen-
demic, and very low (under 1 year) in the hyperendemic areas).
For infectious diseases in general, this effect is usually due to
acquired immunity and it occurs when individuals experiencing
higher forces of infection either develop adaptive protective
immunity earlier or clear their infection more rapidly at younger
ages than they would in environments with lower force of
infection. The observation of this phenomenon here lends further
support to the importance of acquired immunity in trachoma
[27,29].
The recovery rate from infection rises very rapidly with the
number of prior infections and the 95% confidence interval of the
rate of this rise includes extremely large values at the upper end.
This rapidity suggests that the immune response to the first few
infections is qualitatively different to that of the bulk of subsequent
infections and therefore the maturation of trachoma immunity
occurs after only few infections, a finding that may also be
associated with limited variation in the pathogen population.
Indeed, the possibility of extremely large values for the rate at
which the duration of infection changes with the number of
infections (unbounded upper confidence limit of the rate c,i n
Table 2), suggests that the data are consistent with the
development of immunity following a single initial infection. The
data for the recovery rate from infection (plotted in Figure 3B as its
reciprocal, the average duration of infection) used in the model
were on average lower than the estimates reported by Bailey et al.
[7]—who used a test for infection less sensitive than PCR-based
testing and may have found longer durations (i.e. lower recovery
rates) with a more sensitive test—and instead corresponded with a
newer analysis of the same data [3] (where the mean duration of
infection was found to be around 5 months for young children (,5
years old) and under 3 months for older people (.15 years old)). If
the rates of recovery in the model were not as low as those used in
this work, the peak in infection prevalence, for settings with lower
endemicity, would not occur at ages corresponding to those
observed in the data. In the hyperendemic setting, the peak
prevalence occurs at a very early age becoming barely perceptible
due to its large transmission rate; this causes individuals rapidly to
acquire infections from a very young age.
Infection bacterial loads are explicitly included in the model; the
chlamydial loads for those who have experienced few infections
are typically higher than for those who have experienced many.
The reason behind this difference is thought to be the
development of acquired immunity through repeated exposure
to the bacteria that, although it does not protect from incoming
infection, may reduce its intensity.
A model structure in which pathogen load is explicitly
accounted for has been used extensively to model helminth
infections, by assuming that acquired immunity to infection may
be developed with cumulative infection experience and therefore
with age, leading to peaked age-profiles of infection intensity and
prevalence [29–31]. Age-specific changes in exposure are also
likely to contribute to this pattern [32,33], and indeed the peaked
distributions observed in the model and the data for ocular
chlamydial infection and disease are the result of both changes in
the duration of infection and patterns of exposure to infection with
age.
The prevalence levels of the disease sequelae were modeled
under the assumption that individuals who had experienced
greater than or equal to a specific threshold number of infections
would begin to show signs of the ocular sequelae. Threshold
infection numbers were therefore estimated corresponding to each
of TS and TT; these calculations were performed for the
hyperendemic setting, because it would only be in communities
where there has been no intervention (at true endemic
equilibrium) that the transmission and repeat infection rates will
give rise to current disease sequelae prevalence levels. The
threshold infection numbers for TS and TT estimated in this
paper are dependent upon the data we have used for the duration
of infection and infection load; a higher duration, for example,
would decrease these estimates and so these values are contingent
upon future longitudinal studies. In those communities (the hypo-
and mesoendemic areas in this paper) where there has been either
some intervention or possibly a secular trend that has reduced
transmission, the prevalence of those suffering from sequelae will,
for some time, remain much higher than the current transmission
level would suggest. Another explanation for differences here is the
possibility that only a given fraction of the population progresses to
Figure 5. The age-dependent prevalence of the disease
sequelae in a hyperendemic setting. Prevalence curves for
trachomatous scarring (solid line) and trachomatous trichiasis (dotted
line) are shown along with the data from [28] (circles (TS) and squares
(TT) and 95%CI error bars), which were collected from the same district
as the data of West et al. [25] during the mid-1990s, prior to drug
treatment interventions. An assumption made here is that the incidence
of the sequelae did not change over the decade prior to the first mass
drug administration.
doi:10.1371/journal.pntd.0000462.g005
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populations due to factors such as the genetic predisposition to
scarring of particular individuals in each population [34–41].
Although our working hypothesis is that repeat chlamydial
infection is the main route to the severe disease sequelae, it may
not be the only one. Some studies show that, once established,
scarring complications may continue to progress, perhaps driven
by factors other than Chlamydia spp., such as non-chlamydial
bacterial infection [42]. Trachomatous CO leading to blindness
probably has a multi-factorial etiology. These effects will be
examined in future work and may lead to lower threshold infection
numbers than those calculated here.
In summary, the balance between ocular exposure to C.
trachomatis and acquired immunity, which is presumed to reduce
the intensity and duration of infection, leads to the expected shape
and magnitude of the age-profiles of infection prevalence observed
in settings of variable endemicity. Data used in the model for the
recovery rate from infection [3] led to lower corresponding
parameter estimates than those previously reported [7], closer to
those used in other trachoma models [5], although these models
do not allow for an age-dependent recovery rate, nor do they
investigate the relationship between infection and disease or
incorporate chlamydial load. For the (hyperendemic) setting in
which levels of current infection are those responsible for observed
morbidity, the model captures well the progression of scarring with
age and reproduces the observed age-profiles of ocular sequelae
prevalence. Future work will investigate the effect of the ‘A’
component of the SAFE strategy (mass administration of
antibiotics) on the age-profiles of infection and disease, and will
present the implications of this model for trachoma control policy.
Supporting Information
Text S1 Mathematical model outline and details on the
likelihood.
Found at: doi:10.1371/journal.pntd.0000462.s001 (0.14 MB
DOC)
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